Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;102(10):3808-15.
doi: 10.1002/jps.23667. Epub 2013 Jul 22.

Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs

Harikrishna Devalapally  1 , Svitlana Silchenko, Feng Zhou, Jessica McDade, Galina Goloverda, Albert Owen, Ismael J Hidalgo
Affiliations

Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs

Harikrishna Devalapally et al. J Pharm Sci. 2013 Oct.

Abstract

The objective of this study was to determine whether nanoemulsion formulations constitute a viable strategy to improve the oral bioavailability of danazol, a compound whose poor aqueous solubility limits its oral bioavailability. Danazol-containing oil-in-water nanoemulsions (NE) with and without cosurfactants stearylamine (SA) and deoxycholic acid (DCA) were prepared and characterized. Nanoemulsion droplets size ranging from 238 to 344 nm and with surface charges of -24.8 mV (NE), -26.5 mV (NE-DCA), and +27.8 mV (NE-SA) were reproducibly obtained. Oral bioavailability of danazol in nanoemulsions was compared with other vehicles such as PEG400, 1% methylcellulose (MC) in water (1% MC), Labrafil, and a Labrafil/Tween 80 (9:1) mixture, after intragastric administration to rats and after oral administration of NE-SA, a Labrafil solution, or a Danocrine® tablet to dogs. The absolute bioavailability of danazol was 0.6% (PEG400), 1.2% (1% MC), 6.0% (Labrafil), 7.5% (Labrafil/Tween80), 8.1% (NE-DCA), 14.8% (NE), and 17.4% (NE-SA) in rats, and 0.24% (Danocrine), 6.2% (Labrafil), and 58.7% (NE-SA) in dogs. Overall, danazol bioavailability in any nanoemulsion was higher than any other formulation. Danazol bioavailability from NE and NE-SA was 1.8- to 2.2-fold higher than NE-DCA nanoemulsion and could be due to significant difference in droplet size.

Keywords: absorption; bioavailability; danazol; hepatic clearance; nanoemulsion; particle size; stearylamine; surfactants.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Average Plasma Concentration (ng/mL) of Danazol vs Time Following Intravenous Administration to (•) Rats (0.65 mg/kg); and (▲) Dogs (1 mg/kg) in aqueous 10%HPßCD. The data are mean ± SD of the results from 3 animals.
Figure 2
Figure 2
Average Plasma Concentration (ng/mL) of Danazol vs Time Following Oral Administration to Rats A) 10 mg/kg from PEG400 (•), 1%MC (▲), Labrafil (◆), and Labrafil +Tween 80 (9:1) (▪); B) 12 mg/kg from NE (•), 11.3 mg/kg from NE-SA (▲) and 17.5 mg/kg from NE-DCA (◆). The data are mean ± SD of the results from 3 animals.
Figure 2
Figure 2
Average Plasma Concentration (ng/mL) of Danazol vs Time Following Oral Administration to Rats A) 10 mg/kg from PEG400 (•), 1%MC (▲), Labrafil (◆), and Labrafil +Tween 80 (9:1) (▪); B) 12 mg/kg from NE (•), 11.3 mg/kg from NE-SA (▲) and 17.5 mg/kg from NE-DCA (◆). The data are mean ± SD of the results from 3 animals.
Figure 3
Figure 3
Average Plasma Concentration (ng/mL) of Danazol vs Time Following Oral Administration to Dogs at 20 mg/kg in Danocrine Tablet (•), 5 mg/kg in Labrafil Solution (▲) and 7.16 mg/kg in NE-SA (◆). The data are mean ± SD of the results from 3 animals.
See this image and copyright information in PMC

References

    1. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, Kuo M, Hageman MJ. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci. 2003;92:2386–2398. - PubMed
    1. Ansell SM, Johnstone SA, Tardi PG, Lo L, Xie S, Shu Y, Harasym TO, Harasym NL, Williams L, Bermudes D, Liboiron BD, Saad W, Prud'homme RK, Mayer LD. Modulating the therapeutic activity of nanoparticle delivered paclitaxol by manipulating the hydrophobicity of prodrug conjugates. J Med Chem. 2008;51:3288–3296. - PubMed
    1. Masuda A, Goto Y, Kurosaki Y, Tetsuya A. In vivo application of chitosan to facilitate intestinal acyclovir absorption in rats. J Pharm Sci. 2012;101:2449–2456. - PubMed
    1. Larsen A, Holm R, Pedersen ML, Mülletz A. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm Res. 2008;25:2769–2777. - PubMed
    1. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201–230. - PubMed

Publication types

LinkOut - more resources